Education
About Us
Working with TipRanks
Follow Us
Cormedix (CRMD)
NASDAQ:CRMD
CRMD Stock Chart & Stats
$7.58
$0.06(0.58%)
At close: 4:00 PM EST
$7.58
$0.06(0.58%)
Day’s Range― - ―
52-Week Range$5.60 - $17.43
Previous CloseN/A
Volume1.29M
Average Volume (3M)3.42M
Market Cap
$597.22M
Enterprise Value$697.97M
Total Cash (Recent Filing)$55.72M
Total Debt (Recent Filing)$148.92M
Price to Earnings (P/E)3.7
Beta1.48
Next Earnings
Mar 31, 2026EPS Estimate
0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.26
Shares Outstanding78,789,050
10 Day Avg. Volume2,334,010
30 Day Avg. Volume3,417,953
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)5.63
Price to Sales (P/S)10.97
P/FCF Ratio-9.40
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue3.26
Enterprise Value/Gross Profit3.52
Enterprise Value/Ebitda6.22
Forecast
1Y Price Target
$13.67Price Target Upside80.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Strategic DiversificationA substantial cash and short-term investment position combined with the completed Melinta acquisition provides financial flexibility and a more diversified revenue base while clinical and pricing catalysts develop.
Clinical Trial ReadoutsAnalyst attention is focused on the Rezzayo phase three trial results as a primary upside catalyst, since positive efficacy or safety data could materially expand the market opportunity and lift valuation.
Real-world Evidence And Market AccessReal-world evidence showing large reductions in catheter-related bloodstream infections and related hospitalizations supports payer engagement, and leveraging that data to broaden access and penetrate Medicare Advantage could drive sustainable volume recovery.
Bears Say
Market Sentiment And Liquidity RiskDivergence between management guidance and analyst views, together with elevated short interest and constrained liquidity, could amplify trading volatility and increase downside risk if upcoming catalysts disappoint.
Reimbursement Transition And Pricing PressureAn anticipated reimbursement transition is expected to compress net pricing for DefenCath, creating a material near-term headwind that could significantly reduce revenue under the current label.
Revenue Guidance And Consensus MissCompany revenue guidance and preliminary results below analyst expectations have reset investor forecasts and prompted downward adjustments to valuation assumptions.
Cormedix News
CRMD FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was $5.60 and its highest was $17.43 in the past 12 months.
What is Cormedix’s market cap?
Cormedix’s market cap is $597.22M.
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is Mar 31, 2026 which is in 47 days.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Nov 12, 2025. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $0.634 by $0.626.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is 0.82.
How many shares outstanding does Cormedix have?
Cormedix has 78,789,050 shares outstanding.
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of $1.26 in its last earnings report, beating expectations of $0.634. Following the earnings report the stock price went up 2.055%.
Which hedge fund is a major shareholder of Cormedix?
Currently, no hedge funds are holding shares in CRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cormedix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.67 (80.34% Upside)
$13.67 (80.34% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.39%
12-Months-Change
Fundamentals
Return on Equity
75.08%
Trailing 12-Months
Asset Growth
867.78%
Trailing 12-Months
Company Description
Cormedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CRMD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted a transformative quarter for CorMedix, marked by record financial performance, strategic acquisitions, and promising future growth catalysts. Despite increased operating expenses and uncertainties surrounding DefenCath's post-TDAPA pricing, the company's strong revenue growth and strategic investments indicate a positive outlook.View all CRMD earnings summariesCRMD Stock 12 Month Forecast
Average Price Target
$13.67
▲(80.34% Upside)
Technical Analysis
Arbutus Biopharma
―
Immatics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Zenas BioPharma, Inc.
―
Ownership Overview
2.05% Insiders
7.89% Mutual Funds
0.66% Other Institutional Investors
77.61% Public Companies and Individual Investors